Cargando…
Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies
Fast, accurate and reliable methods to quantify the amount of myelin still lack, both in humans and experimental models. The overall objective of the present study was to demonstrate that sphingomyelin (SM) in the cerebrospinal fluid (CSF) of patients affected by demyelinating neuropathies is a myel...
Autores principales: | Capodivento, Giovanna, Visigalli, Davide, Garnero, Martina, Fancellu, Roberto, Ferrara, Michela Demetra, Basit, Abdul, Hamid, Zeeshan, Pastore, Vito Paolo, Garibaldi, Silvano, Armirotti, Andrea, Mancardi, Gianluigi, Serrati, Carlo, Capello, Elisabetta, Schenone, Angelo, Nobbio, Lucilla |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552737/ https://www.ncbi.nlm.nih.gov/pubmed/28798317 http://dx.doi.org/10.1038/s41598-017-08314-1 |
Ejemplares similares
-
CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS
por: Capodivento, Giovanna, et al.
Publicado: (2021) -
Exploiting Sphingo- and Glycerophospholipid Impairment to Select Effective Drugs and Biomarkers for CMT1A
por: Visigalli, Davide, et al.
Publicado: (2020) -
COVID-19-related and not related Guillain-Barré syndromes share the same management pitfalls during lock down: The experience of Liguria region in Italy
por: Garnero, Martina, et al.
Publicado: (2020) -
Myelination, Dysmyelination, and Demyelination
por: Jean Harry, G., et al.
Publicado: (1998) -
Deoxysphingolipids as candidate biomarkers for a novel SPTLC1 mutation associated with HSAN-I
por: Boso, Federica, et al.
Publicado: (2019)